Phosphate binders and management of hyperphosphataemia in end-stage renal disease

Nephrology Dialysis Transplantation

Volumn 21, Issue 8, 2006, Pages 2065-2068

  Savica, Vincenzo ^a   Calò, Lorenzo A ^b   Monardo, Pietro ^a   Santoro, Domenico ^a   Bellinghieri, Guido ^a  

^a UNIVERSITY OF MESSINA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Hyperphosphataemia; Phosphate binders; Renal failure; Vascular calcifications

Indexed keywords

ALUMINUM CARBONATE; ALUMINUM HYDROXIDE; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; IRON DERIVATIVE; LANTHANUM CARBONATE; PHOSPHATE; PHOSPHATE BINDING AGENT; PLACEBO; POLYNUCLEAR IRON IDROXIDE; SEVELAMER; UNCLASSIFIED DRUG; VITAMIN D;

ARTERY CALCIFICATION; BLOOD VESSEL CALCIFICATION; BONE DISEASE; BONE MARROW TOXICITY; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CORONARY ARTERY; COST EFFECTIVENESS ANALYSIS; DIALYSIS; DIALYSIS ENCEPHALOPATHY; DIET RESTRICTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COST; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG SOLUBILITY; DRUG TISSUE LEVEL; HEALTH CARE COST; HEART DEATH; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALNUTRITION; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE INTAKE; PRIORITY JOURNAL; REVIEW; SECONDARY HYPERPARATHYROIDISM; UNSPECIFIED SIDE EFFECT;

ACETATES; ALUMINUM COMPOUNDS; BONE DISEASES, METABOLIC; CALCINOSIS; CALCIUM CARBONATE; CALCIUM COMPOUNDS; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM DISEASES; DIET, PROTEIN-RESTRICTED; FERRIC COMPOUNDS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; LANTHANUM; PHOSPHATES; PHOSPHORUS, DIETARY; POLYAMINES; RENAL DIALYSIS; RENAL OSTEODYSTROPHY;

EID: 33748059188     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl289     Document Type: Review

References (41)

1. Guérin AP, London GM, Marchais SJ, Metivier F. Arterial stiffening and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant 2000; 15: 1014-1021
2. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483
3. Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am J Kidney Dis 2000; 35: 1226-1237
4. Floege J, Ketteler M. Vascular calcification in patients with endstage renal disease. Nephrol Dial Transplant 2004; 19 [Suppl 51]: V59-V66
5. Goldsmith D, Ritz E, Covic A. Vascular calcification: A stiff challenge for the nephrologist. Kidney Int 2004; 66: 1315-1333
6. Amann K, Tornig J, Kugel B et al. Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 2003; 63: 1296-1301
7. Eknoyan G, Levin A, Levin NW. National Kidney Foundation. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 [Suppl 3]: S1-S201
8. Kopple JD. National Kidney Foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 37 [Suppl 2]: S66-S70
9. Mallick NP, Gokal R. Haemodialysis. Lancet 1999; 353: 737-742
10. Alfrey AC, Legendre GR, Kaehny WD. Dialysis encephalopathy syndrome: possible aluminum intoxications. N Engl J Med 1976; 294: 184-188
11. Hewitt CD, Savory J, Wills MR. Aspects of aluminum toxicity. Clin Lab Med 1990; 10: 403-422
12. Goodman WG. Bone disease and aluminum: Pathogenic considerations. Am J Kidney Dis 1985; 6: 330-335
13. Ritz E. Managing mineral balance in end-stage renal disease. Nephrol Dial Transplant 2004; 19 [Suppl 1]: S1-S3
14. Slatopolsky E, Weerts C, Lopez-Hilker S et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157-161
15. Emmett M, Sirmon M, Kirkpatrick W et al. Calcium acetate control of serum phosphorus in hemodialysis patients. Am J Kidney Dis 1991; 5:544-550
16. Chertow GM, Dillon MA, Amin N, Burke SK. Sevelamer with and without calcium and vitamin D: Observations from a longterm open-label clinical trial. J Ren Nutr 2000; 10: 125-132
17. Burke SK, Slatopolsky E, Goldberg DI. Renagel, a novel calcium- and aluminum-free phosphate binder, inhibits phosphate absorption in normal volunteers. Nephrol Dial Transplant 1997; 12: 1640-1644
18. Slatopolsky E, Burke SK, Dillon MA. and The Renagel Study Group. Renagel, a nonabsorbed calcium- and aluminum free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: 299-307
19. Goldberg DI, Dillon MA, Slatopolsky E et al. Effect of Renagel, a non absorbed, calcium and aluminum free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end stage renal disease patients. Nephrol Dial Transplant 1998; 13: 2303-2310
20. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrocloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701
21. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. For the Renagel Study Group. Long-term effects of sevelamer hydrocloride on the calcium x phosphate product and lipid profile of hemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914
22. Emmett M. A comparison of clinically useful phosphorus binders for patients with chronic kidney failure. Kidney Int 2004; 90 [Suppl]: S25-S32
23. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62: 245-252
24. Nagano N, Miyata S, Abe M et al. Sevelamer hydrochloride reverses parathyroid gland enlargement via regression of cell hypertrophy but not apoptosis in rats with chronic renal insufficiency. Nephrol Dial Transplant 2006; 21: 634-643
25. Raggi P. Detection and quantification of cardiovascular calcifications with electron beam tomography to estimate risk in hemodialysis patients Clin Nephrol 2000; 54: 325-333
26. Raggi P. Effects of excess calcium load on the cardiovascular system measured with electron beam tomography in end-stage renal disease. Nephrol Dial Transplant 2002; 17: 332-335
27. Behets GJ, Verberckmoes SC, D'Haese PC, De Broe ME. Lanthanum carbonate: a new phosphate binder. Curr Opin Nephrol Hypertens 2004; 13: 403-409
28. Locatelli F, D'Amico M, Pontoriero G. Lanthanum carbonate. Drugs 2003; 6: 688-695
29. Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 2003; 42: 96-107
30. Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: A 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004; 19: 1902-1906
31. Finn WF. SPD 405-307 Lanthanum, Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: Safety and efficacy in chronic maintenance hemodialysis patients. Clin Nephrol 2006; 65: 202
32. Damment SJP, Gill M. The pharmacokinetics and tissue distribution of lanthanum carbonate (Fosrenol), a new non-aluminum, non-calcium phosphate binder [Abstract]. J Am Soc Nephrol 2003; 14: 204A
33. Lacour B, Lucas A, Auchere D, Ruellan N, De Serre Patey NM, Drueke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67: 1062-1069
34. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005; 68: 2809-2813
35. Behets GJ, Dams G, Damment S et al. Does the phosphate binder lanthanum carbonate affect bone in chronic renal failure rats? J Am Soc Nephrol 2004; 15: 2219-2228
36. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 63 [Suppl]: S73-S78
37. Freemont T, Malluche HH. Utilization of bone histomorphometry in renal osteodystrophy: Demonstration of a new approach using data from a prospective study of lanthanum carbonate. Clin Nephrol 2005; 63: 138-145
38. Graff L, Burnel D. Reduction of dietary phosphorus absorption by oral phosphorus binders. Res Commun Mol Pathol Pharmacol 1995; 90: 389-401
39. Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant 2004; 19 [Suppl 1]: I19-i24
40. Hutchison AJ, Maes B, Vanwalleghem J et al. Long-term efficacy and tolerability of lanthanum carbonate: Results from a 3-year study. Nephron Clin Pract 2006; 102: C61-c71
41. Hergesell O, Ritz E. Stabilized polynuclear iron hydroxide is an efficient oral phosphate binder in uraemic patients. Nephrol Dial Transplant 1999; 14: 863-867